Skip to main content

Berger Disease clinical trials at UCSF

1 research study open to eligible people

Showing trials for
  • A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)

    open to eligible people ages 18-65

    The purpose of this study is to evaluate the effect of cemdisiran on proteinuria in adults with immunoglobulin A nephropathy (IgAN), who excrete >1 gram (gm) of protein per day despite standard of care, which includes treatment with angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs). These patients are at high risk for progression of kidney disease, which can result in end-stage renal failure.

    San Francisco, California and other locations

Last updated: